Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Consensus Price Target of $290.00 According to Analysts

Key Points

• Analysts are moderately bullish on CRL: 13 of 17 analysts rate the stock a buy, with an average 12-month price target of $290. Recent targets range as high as $330.
• Charles River Laboratories’ shares opened at $296.02, near their 52-week high of $303.30, after rising 0.5%. The company exceeded quarterly earnings expectations with EPS of $3.02 versus a $2.77 consensus, though revenue declined 2.7% year over year.
• Institutional investors own 98.91% of the company, while insiders sold 90,990 shares worth $25.7 million during the latest quarter. The company projects fiscal 2026 EPS of $11.15–$11.45.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seventeen ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $290.00.

CRL has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the company a "buy" rating in a research note on Friday. Argus set a $330.00 price target on Charles River Laboratories International in a research report on Thursday, September 17th. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. Morgan Stanley boosted their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Finally, Royal Bank Of Canada upped their price objective on Charles River Laboratories International from $282.00 to $322.00 and gave the company an "outperform" rating in a research note on Friday, September 25th.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CEO Birgit Girshick sold 6,500 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the sale, the chief executive officer directly owned 36,013 shares of the company's stock, valued at $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company's stock, valued at approximately $1,264,241. This trade represents a 51.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 90,990 shares of company stock valued at $25,731,388 in the last quarter. Insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its holdings in Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock valued at $285,001,000 after purchasing an additional 210,260 shares during the period. Geode Capital Management LLC grew its position in Charles River Laboratories International by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company's stock worth $254,186,000 after acquiring an additional 9,756 shares in the last quarter. Bank of America Corp DE increased its position in shares of Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company's stock valued at $195,792,000 after purchasing an additional 54,500 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in Charles River Laboratories International by 8.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 836,240 shares of the medical research company's stock valued at $166,813,000 after acquiring an additional 66,803 shares during the last quarter. Finally, Amundi grew its holdings in shares of Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after purchasing an additional 492,301 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Up 0.5%

NYSE:CRL opened at $296.02 on Wednesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The firm has a 50-day moving average of $273.48 and a 200-day moving average of $215.08. The company has a market cap of $14.13 billion, a PE ratio of -61.03, a PEG ratio of 2.87 and a beta of 1.40. Charles River Laboratories International has a one year low of $146.20 and a one year high of $303.30.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping the consensus estimate of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the business posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts expect that Charles River Laboratories International will post 11.42 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.